As reported in Table 3, high survivin expression was significantly associated with TNM stage (III/IV vs. I/II: RR, 2.75; 95% CI: 2.21–3.44; p < 0.001), pathological T stage (T3/T4 vs. T1/T2: RR, 2.19; 95% CI: 1.75–2.75; p < 0.001), lymph node metastasis (yes vs. no: RR, 2.28; 95% CI: 1.61–3.25; p < 0.001), distant metastasis (yes vs. no: RR, 1.56; 95% CI: 1.16–2.08; p = 0.003), Fuhrman grade (III/IV vs. I/II: RR, 2.81; 95% CI: 2.29–3.45; p < 0.001), and tumor size (>7 vs. ≤7: RR, 1.49; 95% CI: 1.24–1.78; p < 0.001). Here, BIRC5 is linked to metastatic malignant neoplasm in the lymph nodes.